Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. - Wikidata - awgldk - TriplyDB

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.

http://www.wikidata.org/entity/Q34115910

about

DNA methylation biomarkers: cancer and beyond DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract Validation study of genes with hypermethylated promoter regions associated with prostate cancer recurrence.Performance evaluation of kits for bisulfite-conversion of DNA from tissues, cell lines, FFPE tissues, aspirates, lavages, effusions, plasma, serum, and urine.Clinical performance validation of PITX2 DNA methylation as prognostic biomarker in patients with head and neck squamous cell carcinoma.TGF-β mediated DNA methylation in prostate cancer.DNA methylation gene-based models indicating independent poor outcome in prostate cancer.Methylation of APC and GSTP1 in non-neoplastic tissue adjacent to prostate tumour and mortality from prostate cancer.ERManI is a target of miR-125b and promotes transformation phenotypes in hepatocellular carcinoma (HCC)Improved PCR performance using template DNA from formalin-fixed and paraffin-embedded tissues by overcoming PCR inhibition.Bisulfite Conversion of DNA from Tissues, Cell Lines, Buffy Coat, FFPE Tissues, Microdissected Cells, Swabs, Sputum, Aspirates, Lavages, Effusions, Plasma, Serum, and Urine.PITX3 DNA methylation is an independent predictor of overall survival in patients with head and neck squamous cell carcinoma.A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors.PITX2 and PANCR DNA methylation predicts overall survival in patients with head and neck squamous cell carcinoma RHCG and TCAF1 promoter hypermethylation predicts biochemical recurrence in prostate cancer patients treated by radical prostatectomy.Diagnostic and prognostic molecular biomarkers for prostate cancer.DNA methylation biomarkers in cancer: progress towards clinical implementation.Methylation markers for prostate cancer prognosis: a systematic review.Prostate cancer epigenetic biomarkers: next-generation technologies.Nucleic acid-based tissue biomarkers of urologic malignancies.Prognostic DNA methylation markers for prostate cancer.The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer.DNA Methylation and Urological Cancer, a Step Towards Personalized Medicine: Current and Future Prospects.Large-scale evaluation of SLC18A2 in prostate cancer reveals diagnostic and prognostic biomarker potential at three molecular levels Methylation of PITX2, HOXD3, RASSF1 and TDRD1 predicts biochemical recurrence in high-risk prostate cancer.PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy.CDO1 promoter methylation is associated with gene silencing and is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients.The SNP rs6441224 influences transcriptional activity and prognostically relevant hypermethylation of RARRES1 in prostate cancer.Ability of PITX2 methylation to predict survival in patients with prostate cancer.DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.Epigenome-Wide Tumor DNA Methylation Profiling Identifies Novel Prognostic Biomarkers of Metastatic-Lethal Progression in Men Diagnosed with Clinically Localized Prostate Cancer.Comprehensive Evaluation of TFF3 Promoter Hypomethylation and Molecular Biomarker Potential for Prostate Cancer Diagnosis and Prognosis.DNA methylation in promoter region as biomarkers in prostate cancer.Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer.The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges.Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.Markers of clinical utility in the differential diagnosis and prognosis of prostate cancer.Current research on head and neck cancer-associated long noncoding RNAs.A DNA hypermethylation profile reveals new potential biomarkers for the evaluation of prognosis in urothelial bladder cancer.

P2860

Q26996421-CFAEFA58-2721-4B16-BDB5-C5C8812E148F Q28109676-20568329-C3E5-4F04-B8FA-E66D39299AFA Q30582750-EA43CFF3-6D2A-44D0-8321-94C3B973F4C9 Q31157538-BC12C6BF-D887-4A4C-A1CA-20CB7185C7C5 Q33803297-CC66128B-6899-4FA5-B0A5-AE5FC3F65A31 Q34039935-D56FA786-527E-4D04-A28F-F72D760C3E34 Q34174356-C272D7BA-A65C-4507-AD46-91D19A08A84C Q34847101-568925C0-53BE-4CB1-A35C-9130BCA42FFA Q34938492-0A88D866-483F-4F4B-AB2C-9132E2E95C09 Q35025525-F8AB31A4-C790-4434-A57B-4918E849D093 Q35681956-B3023CE7-C29F-457A-B40C-3338D1961A6A Q37623044-A29DD0D2-51EB-408B-A54A-6A5385C5B11E Q37687723-B38FCF93-0D0A-4909-A117-17C3CA37B3D7 Q37689028-31EC8E6C-4E6E-4303-8C72-5B4EF1BDED12 Q37701479-BF871EA1-C6E9-4C1C-A943-1FD40F004877 Q37972703-4CED003E-AB4B-40A8-86FE-E8F0728F4230 Q38018995-27EA6657-3244-4DF0-80E9-916933CDF535 Q38116745-317F73ED-4FC5-4BAC-9518-F6B6F53D67A3 Q38212471-74043E54-CBEB-4877-B86E-3B375662252E Q38216131-FA099E5C-11A3-4829-B90A-E4A3FFC72A73 Q38252624-BB9F41D4-F24A-4A70-9D45-38039EEDED8A Q38269155-8661F5BD-D51D-490A-8B5F-F9448F01F849 Q38311617-A2BBA4AD-D1FC-4EF0-B1B5-038AFDD0B2F8 Q38833395-30EE892C-B20F-4EC7-9281-60F99DE518AC Q38904571-F1CC8DC7-8A99-488F-9EB2-668A821583D8 Q38983831-0716ECE4-3DEB-4D27-B23A-A90B40F6D0EC Q39318240-A0370094-8DAD-4AAC-B360-084DF48FACE4 Q39334962-5D514D05-C136-4BF0-B9AF-940FD7B87B65 Q39351158-D224B63A-4442-47AB-BC5A-29ED529904DB Q40230694-C7761DA8-0D0A-4174-8DC8-FA27C60FB3A7 Q40581966-E368FA5D-356A-4B2B-BBB8-87B60527C1C0 Q40674443-FE091395-0700-447D-BC5C-4D59FFC98833 Q41660235-83CCABEB-23F7-4DF6-86A2-3BB9F60ED6FC Q42261678-72589E98-0D76-41A8-A6CE-1FBA5793A4F1 Q42950544-803B62CC-F65B-4930-A75B-E484A5AC1E88 Q43375967-DF366DE8-8D84-466E-A81E-7A54D25AE89E Q44019552-49F41E4F-43E2-480A-BAC1-C07C8AC9A1A8 Q47215343-2E3BD981-3860-4C2D-B7F4-A314D1FDA7AA Q49273546-75101700-C9AE-4C4B-B87A-598E9FA7B4D9 Q50957337-77F62152-9CB6-4B94-9B98-B92767249FA7

P2860

Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.

http://www.wikidata.org/entity/Q34115910

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@ast

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@en

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@nl

type

label

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@ast

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@en

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@nl

prefLabel

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@ast

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@en

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@nl

P1433

Q34115910-4A1C764F-31B6-459B-9205-7CDAF44F9175

P1476

Q34115910-D7480AED-712A-4C68-97F0-10463CE4CBCD

P2093

Q34115910-0F39185D-9DB8-4CCD-BAFA-8B9FAAA3A8A1

Q34115910-0FF24A61-E3BD-4031-8943-3EA0907BA2FF

Q34115910-30466C9F-610C-4052-AD34-957C8899C376

Q34115910-396BF1A3-B403-4279-A563-7DDBB37F2003

Q34115910-52CEAA84-6A2E-4E78-908E-417084429AE7

Q34115910-599BE98B-C92E-492E-B5DD-1CA80A092A51

Q34115910-7FAA141F-7D1F-4AAA-833A-1788E71B8A54

Q34115910-8D14E3C3-E4CB-460D-8332-09905076917F

Q34115910-9664ED5D-78DF-4187-B1F0-F74CAF674F2E

Q34115910-9EA6D402-C401-41CA-8CB1-5D568ADB779D

P304

Q34115910-9A82D5E9-1B8E-49F6-B0C1-AB899AFD1E9E

P31

Q34115910-EDA34A57-AE5E-4FCD-BC2C-83BEB263BB37

P356

Q34115910-DC03DE87-D83C-43E6-968B-B3F59A76FB4B

P407

Q34115910-231CF97C-42DB-431A-80B5-4B5CAB8A3761

P433

Q34115910-47BE5391-96D5-4067-8C83-8296FD757E2B

P478

Q34115910-B560BD38-2676-450A-936F-80E05D1253DC

P577

Q34115910-CA1A9D95-4732-471A-A089-CD6D8386AF55

P698

Q34115910-87E37AA3-3CAB-45A9-BB1C-979F56B95127

P921

Q34115910-5F4F1091-2114-4A01-9377-BDFE210B04A9

P356

J.JURO.2010.03.012

P1433

The Journal of Urology

P1476

Multicenter clinical validatio ...... prostatectomy prostate cancer.

@en

P2093

Amy L Lark

http://www.w3.org/2001/XMLSchema#string

Arndt Hartman

http://www.w3.org/2001/XMLSchema#string

Chris H Bangma

http://www.w3.org/2001/XMLSchema#string

Esmeralda Castaños-Vélez

http://www.w3.org/2001/XMLSchema#string

Geert J van Leenders

http://www.w3.org/2001/XMLSchema#string

Gunter Weiss

http://www.w3.org/2001/XMLSchema#string

John F Madden

http://www.w3.org/2001/XMLSchema#string

Leon Sun

http://www.w3.org/2001/XMLSchema#string

Lionel L Bañez

http://www.w3.org/2001/XMLSchema#string

Michael M Ittmann

http://www.w3.org/2001/XMLSchema#string

P304

149-156

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JURO.2010.03.012

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

184

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20478579

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial